A Phase 4 interventional study of Iheezo and Lidocaine pledget in Macular Degeneration, Diabetic Retinopathy and Retinal Vein Occlusion (RVO), sponsored by Retina Consultants of Delmarva. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Retina Consultants of Delmarva · Phase 4, Interventional, and Treatment
Prospective comparative clinical study.
One hundred eyes of 50 patients were included. All patients received bilateral same-day intravitreal injections, with Iheezo administered to only one randomly selected eye and standard topical anesthesia administered to the contralateral control eye. Ocular discomfort was assessed using a 0-10 numeric rating scale at 2 minutes, 1 hour, 6-12 hours, and 24 hours following injection. The primary longitudinal analysis used a linear mixed-effects model incorporating treatment group, assessment time, and treatment-by-time interaction as fixed effects and patient as a random effect. Between-group differences at individual time points were evaluated using Welch two-sample comparisons with Holm adjustment for multiple comparisons. Patient-level mean discomfort across the four assessments was also compared between groups.
1,459 studies on the registry are indexed under Macular Degeneration; 238 are open to participants now.
This study's enrollment of 50 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Retina Consultants of Delmarva is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard anesthesia plus iheezo prior to injection
Drug: Iheezo
Standard anesthesia alone
Drug: Lidocaine pledget
Iheezo applied prior to injection
Standard anesthesia in practice, as proparacaine drops plus lidocaine pledget
Discomfort after injection
Rated 0-10 in each eye
Time frame: 2 minutes to 24 hours after injection
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2026 to primary completion in Aug 2026, 2 months.
Of 45 phase 4 interventional studies under Macular Degeneration, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chloroprocaine
Retina Consultants of Delmarva